International Stem Cell Corp. is a publicly traded biotechnology company with a powerful new stem cell technology called parthenogenesis, which uses unfertilized eggs. It promises to significantly advance the field of regenerative medicine by addressing the problem of immune rejection. The company is focused on using these stem cells to treat diseases of the eye, the nervous system and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.